Skip to main content

Drug Interactions between boceprevir and estropipate

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

estropipate boceprevir

Applies to: estropipate and boceprevir

MONITOR: Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, may decrease the plasma concentrations and efficacy of estrogens used for hormonal replacement therapy. The mechanism involves induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones. When an oral contraceptive containing drospirenone-ethinyl estradiol (3 mg-0.02 mg daily for 14 days) was given in combination with boceprevir (800 mg three times daily for 7 days), ethinyl estradiol systemic exposure (AUC) decreased by approximately 25%, with no change in the peak plasma concentration (Cmax). In a study of 24 subjects who were administered an oral contraceptive containing ethinyl estradiol-norethindrone (0.035 mg-0.5 mg daily) concomitantly with telaprevir (750 mg every 8 hours) for 21 days, the Cmax and AUC of ethinyl estradiol decreased by 26% and 28%, respectively. In addition, there was a 33% reduction in the trough plasma concentration (Cmin) of ethinyl estradiol.

MANAGEMENT: Dosage adjustments as well as increased clinical and laboratory monitoring for estrogen deficiency should be considered whenever boceprevir or telaprevir is used concomitantly with estrogens used for hormonal replacement therapy.

References (3)
  1. (2011) "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation
  2. (2011) "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals
  3. Faculty of Sexual & Reproductive Healthcare (2016) "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf"

Drug and food interactions

Moderate

boceprevir food

Applies to: boceprevir

ADJUST DOSING INTERVAL: Food significantly enhances the oral bioavailability of boceprevir. When given at 800 mg three times daily with food, boceprevir exposure increased by up to 65% relative to administration in the fasting state. The bioavailability of boceprevir was similar regardless of meal type (e.g., high-fat versus low-fat) or whether taken 5 minutes prior to eating, during a meal, or immediately following completion of the meal. Therefore, boceprevir may be taken without regard to either meal type or timing of the meal.

MANAGEMENT: To ensure maximal oral absorption, boceprevir should be administered with a meal or light snack.

References (1)
  1. (2011) "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation
Minor

estropipate food

Applies to: estropipate

Coadministration with grapefruit juice may increase the bioavailability of oral estrogens. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits. In a small, randomized, crossover study, the administration of ethinyl estradiol with grapefruit juice (compared to herbal tea) increased peak plasma drug concentration (Cmax) by 37% and area under the concentration-time curve (AUC) by 28%. Based on these findings, grapefruit juice is unlikely to affect the overall safety profile of ethinyl estradiol. However, as with other drug interactions involving grapefruit juice, the pharmacokinetic alterations are subject to a high degree of interpatient variability. Also, the effect on other estrogens has not been studied.

References (2)
  1. Weber A, Jager R, Borner A, et al. (1996) "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception, 53, p. 41-7
  2. Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T (1995) "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet, 20, p. 219-24

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.